| Ytd | -73.86% | |
| 1y | -87.58% |
| Open | 0.45 | Prev Close | 0.45 | Low | 0.38 | High | 0.46 | Mkt Cap | 22.66M |
| Vol | 1.80M | Avg Vol | 4.09M | EPS | -2.63 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.34 | 200-d Avg | 1.27 | 1yr Est | 7.80 |
MDCX News
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life scie
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life scie
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life scie
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.31) per share which missed the analyst
Medicus Pharma reports dose-response in Phase 2 BCC study, with 200µg cohort showing the strongest e
200μg Cohort Achieves 55% Complete Response at Day 57 Emerging asRegistrational Grade Lead RegimenTh
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estim
Medicus Pharma to present Phase 1 Teverelix data showing dose-dependent estradiol suppression and lo
Medicus Pharma submits Phase 2 design for Teverelix, targeting faster data readouts and lower costs
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.83) per share which missed the analyst
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treate
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treate
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA,
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien
Dow down 800 points, S&P 500 and NASDAQ also fall. Energy sector rises, healthcare dips. BJ repo
US stocks down, Dow falls 300 points. Dow traded at 48,411.44, NASDAQ at 22,741.80, S&P 500 at 6
Medicus Pharma stock surged then slipped after the Phase 2 trial showed a 73% clearance rate for its
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life scie
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided
Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving glo
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided
On December 29, 2025, Medicus Pharma Ltd. (the "Company") entered into an Equity Distributio
The engagement establishes a multi-phase framework to support AI enabled capital efficient developme
D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:MDCX) with a Buy and main
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided b
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided b
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided b
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided b